RESEARCH HIGHLIGHT

08 May 2026

People with a deadly form of pancreatic cancer survive longer on a drug that blocks the activity of a family of mutant proteins.

The drug daraxonrasib shrank or halted the growth of pancreatic tumours (yellow; artist’s illustration) in many of the participants in a small clinical trial. Credit: 3Dmedisphere/Science Photo Library

A groundbreaking cancer drug has shown promise against deadly, hard-to-treat pancreatic tumours in a small clinical trial 1 .

Access options

Access Nature and 54 other Nature Portfolio journals

Get Nature+, our best-value online-access subscription

$32.99 / 30 days

cancel any time

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Rent or buy this article

Prices vary by article type

from $1.95

to $39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Log in

Learn about institutional subscriptions

Read our FAQs

Contact…